The overexpression of FR-α and/or FR-β on cancer cells and myelogenous cells allows for both non-invasive diagnostic imaging of FR-positive cancers and inflammatory processes, and subsequent treatment using folate-based drugs or FR-targeting antibodies. This evidence concerns the gene FOLR2 and cancer.